Latest Histone deacetylase Stories
The mice obtained by researchers at UAB, in addition to being the first of their species cloned in Spain, are the first animals to survive at birth and develop correctly.
Latent HIV genes can be 'smoked out' of human cells. The so-called 'shock and kill' technique, described in a preclinical study in BioMed Central's open access journal Retrovirology, might represent a new milestone along the way to the discovery of a cure for HIV/AIDS.
SHENZHEN, China and SAN DIEGO, May 28 /PRNewswire/ -- Shenzhen Chipscreen Biosciences, Ltd., and HUYA Bioscience International, LLC, today announced that final data from a Phase 1 trial conducted by Chipscreen of the investigational compound chidamide (CS055/HBI-8000) will be presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held from May 29 to June 2, 2009, in Orlando, Florida.
MIT researchers who were previously able to reverse the signs of Alzheimerâ€™s disease in mice have now identified the specific gene involved in the process.
A laboratory study by researchers at Albert Einstein College of Medicine of Yeshiva University suggests that an anti-cancer compound studied for treating blood cancers may also help in treating cancers of the head and neck. The work is reported in the April 28th online edition of the Journal of Pathology.
Pharmacyclics to maintain all US Rights Conference Call to discuss the company's third quarter financial results is scheduled for April 23, 2009 at 11:00 a.m. EDT (8:00 a.m. PDT). SUNNYVALE, Calif., April 17 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc.
Today, during the 87th General Session of the International Association for Dental Research, convening at the Miami Beach Convention Center, a group of scientists from Nihon University
SINGAPORE, Dec. 1 /PRNewswire/ -- S*BIO Pte Ltd today announced the initiation of a Phase 1/2 clinical trial of SB1518, a potent and orally-active JAK2 inhibitor, in leading medical centers in Australia for patients with chronic idiopathic myelofibrosis (CIMF).
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) announced today the presentation of a poster highlighting preclinical synergy of Cyclacel's sapacitabine when given in combination with histone deacetylating agents (HDAC) valproate and vorinostat.
MethylGene, a clinical stage biopharmaceutical company, has announced that Health Canada has approved the company's clinical trial application for MGCD290, a fungal Hos2 histone deacetylase inhibitor to be used in combination with azoles for the treatment of fungal infections.
- A transitional zone between two communities containing the characteristic species of each.